Overview

* KORU Medical Q2 2025 net revenues rise 21% to $10.2 mln

* Gross margin drops to 63.5% on favourable year-ago inventory adjustment, current qtr tariff charges

* Adjusted EBITDA turns positive

Outlook

* Company raises 2025 revenue guidance to $39.5 - $40.5 mln

* KORU Medical ( KRMD ) reiterates full-year gross margin guidance of 61% - 63%

* Company expects positive cash flow from operations for full year 2025

* KORU Medical ( KRMD ) forecasts ending cash balance greater than $8.1 mln for 2025

Result Drivers

* DOMESTIC REVENUE GROWTH - Driven by higher consumable volumes and market share gains from new and existing accounts

* INTERNATIONAL REVENUE GROWTH - Boosted by higher consumable and pump volumes, prefill patient conversions, and expansion into new markets

* PHARMA SERVICES GROWTH - Increased revenues from product sales for clinical trials

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$200,00

Income 0

Q2 Gross 63.5%

Margin

Q2 $6.80

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for KORU Medical Systems Inc ( KRMD ) is $6.00, about 45.3% above its August 5 closing price of $3.28

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)